29 November 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Annual General Meeting Statement

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, will hold its Annual General Meeting (AGM) at 10:00 am today at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO10 5BR.

Dr Adam Hargreaves, Non-Executive Chairman will provide the following statement:

"I am delighted with the progress made by Aptamer Group. Since the fundraising of £2.6m in July this year, we have met our cost-base reduction targets, streamlined our scientific production capabilities, and executed our new commercial growth strategy to deliver optimised products of high quality to our growing customer base.

Attracting new partners has ensured that we are now working with the majority of the larger global pharmaceutical companies, alongside a wealth of diagnostic, healthcare, and niche biotech partners. Particular highlights have included the development of a vertical market platform in fibrosis, in which we are working with AstraZeneca; the progression toward human trials of our deodorant Optimer product with Unilever; and the successful production of an Optimer delivery conjugate to an undisclosed genetic medicines company, with which they are planning pre-clinical trials.

Our increased commercial traction has secured newly signed contracts, currently up to the value of £471,000, which will ensure that the Group's cash runway remains generous, allowing any licensing opportunities to evolve and potentially crystalise over this extended period.

The Board looks forward to updating shareholders on further progress in due course."

The AGM will provide no new material information. Results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.

- Ends -

For further information, please contact: 

About Aptamer Group plc 

Aptamer Group  develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers. Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.  

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.  

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/.